HABP/VABP Podcast Series: Novel Therapeutic Advances to Combat Resistant Gram-Negative Bacteria

0.75 CME
0.75 CPE
45 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

HABP/VABP Podcast Series: Novel Therapeutic Advances to Combat Resistant Gram-Negative Bacteria

Overview

Provider Statement

This continuing education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Shionogi Inc.


Activity Description

Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are among the most prevalent acute infections that occur in hospitalized patients, particularly those in the intensive care unit, and are associated with high mortality risk. Both HABP and VABP are associated with increased utilization of health care resources and greater likelihood of death. Many challenges are associated with managing these disease conditions, but none are greater than the battle against antibiotic resistance. Clinically available potent antibiotics that are active against gram-negative pathogens, such as carbapenem-resistant pathogens, are becoming increasingly scarce in the current era of antibiotic resistance. In this podcast series, expert clinicians discuss the burden of these new infections and the role of new therapies to treat them.


Target Audience

The intended audience for the activity is infectious disease specialists, critical care specialists, pulmonologists, hospital pharmacists, and other health care professionals involved in the management of patients with HABP and/or VABP.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Examine the patterns and mechanisms of carbapenem-resistant, gram-negative bacterial infections.
  • Assess the burden of HABP/VABP in patients infected with resistant gram-negative pathogens, including beta-lactamases and carbapenem-resistant pathogens.
  • Evaluate the clinical evidence for therapies to treat gram-negative bacterial infections such as carbapenem-resistant infections, including the rationale for early initiation of antibiotic treatment.

Activity Chair

Marin H. Kollef, MD
Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine
Professor of Medicine
Division of Pulmonary & Critical Care Medicine
Washington University School of Medicine
Director, Critical Care Research
Director, Respiratory Care Services
Barnes‐Jewish Hospital
St. Louis, MO


Faculty

Jason M. Pogue, PharmD, FCCP, BCIDP
Clinical Professor, Infectious Diseases
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Ann Arbor, MI

M. Cristina Vazquez Guillamet, MD
Assistant Professor of Medicine
John T. Milliken Department of Internal Medicine–Division of Infectious Diseases
Washington University School of Medicine
St. Louis, MO


Planners/Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico  Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.75 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-033-H01-P, effective 12/31/2021. This is a knowledge-based activity and there is no fee to attend.

This enduring material is approved for 1 year from the date of original release, December 31, 2021 to December 30, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate or an ACPE Statement of Credit. Vindico will report pharmacist learners to CPE monitor within 30 days of completion of the activity.


Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant relationship(s)

Marin H. Kollef, MD
Advisor: Merck, Shionogi
Consultant: Merck, Shionogi

Jason M. Pogue, PharmD, FCCP, BCIDP
Consultant: Entasis, GlaxoSmithKline, Melinta, Merck, Shionogi, Spero

M. Cristina Vazquez Guillamet, MD
No relevant financial relationships to disclose.

Planners/Reviewers reports the following relevant relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com